Gelteq Completes Veterinary Trials with Kemin, Demonstrates Bitter Masking Expertise
GELS•On June 12, Gelteq and Kemin completed veterinary palatability trials demonstrating strong canine acceptance of formulations using Gelteq® technology, effectively masking natural bitter compounds. These results validate the gel-based delivery platform for veterinary pharmaceuticals and are expected to bolster strategic partnership discussions with pharmaceutical and animal health organisations.
1. Veterinary Palatability Trial Outcomes
Gelteq and Kemin conducted canine palatability trials evaluating formulations with natural bitter compounds, achieving strong acceptance across all flavor profiles. The gel-based delivery platform masked bitterness effectively while maintaining product integrity and canine willingness to consume.
2. Technology Validation for Veterinary Applications
The trial results validate Gelteq® technology as a versatile veterinary drug delivery system capable of improving palatability of active pharmaceutical ingredients. This success broadens the range of formulations and active compounds that can be incorporated into veterinary therapeutics using the gel platform.
3. Strategic Partnership and Market Impact
Positive outcomes are expected to enhance Gelteq’s position in the animal health sector and accelerate strategic discussions with pharmaceutical and animal health organizations. Demonstrated performance in masking bitterness should support pipeline development and foster new partnership opportunities in veterinary pharmaceutical markets.
